Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMA NASDAQ:ME NASDAQ:OKYO NASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMAImageneBio$5.83+1.9%$5.73$3.94▼$18.00$60.89M0.731.02 million shs33,742 shsME23andMe$0.61$0.50$0.53▼$9.57$16.27M1.191.57 million shsN/AOKYOOKYO Pharma$1.60-4.8%$1.63$1.32▼$3.35$68.13M-0.0184,930 shs33,199 shsPYRGFPyroGenesis Canada$0.30+1.8%$0.36$0.12▼$0.53$61.98M0.2655,455 shs9,341 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMAImageneBio0.00%-2.92%+13.88%-19.60%-62.27%ME23andMe0.00%0.00%0.00%+21.75%+21.75%OKYOOKYO Pharma0.00%+5.06%-1.19%-20.95%+21.83%PYRGFPyroGenesis Canada0.00%+0.58%-24.25%+61.61%-9.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMAImageneBio$5.83+1.9%$5.73$3.94▼$18.00$60.89M0.731.02 million shs33,742 shsME23andMe$0.61$0.50$0.53▼$9.57$16.27M1.191.57 million shsN/AOKYOOKYO Pharma$1.60-4.8%$1.63$1.32▼$3.35$68.13M-0.0184,930 shs33,199 shsPYRGFPyroGenesis Canada$0.30+1.8%$0.36$0.12▼$0.53$61.98M0.2655,455 shs9,341 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMAImageneBio0.00%-2.92%+13.88%-19.60%-62.27%ME23andMe0.00%0.00%0.00%+21.75%+21.75%OKYOOKYO Pharma0.00%+5.06%-1.19%-20.95%+21.83%PYRGFPyroGenesis Canada0.00%+0.58%-24.25%+61.61%-9.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMAImageneBio 2.00Hold$26.50354.55% UpsideME23andMe 0.00N/AN/AN/AOKYOOKYO Pharma 2.40Hold$6.33295.83% UpsidePYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ME, OKYO, IMA, and PYRGF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026OKYOOKYO Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)2/20/2026OKYOOKYO Pharma Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$7.002/20/2026OKYOOKYO Pharma Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$7.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMAImageneBio$800K77.61N/AN/A$11.91 per share0.49ME23andMe$208.78M0.08$0.65 per share0.93$2.34 per share0.26OKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/APYRGFPyroGenesis Canada$9.14M6.78N/AN/A($0.01) per share-30.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMAImageneBio-$45.35M-$8.07N/AN/AN/AN/A-35.77%-31.78%N/AME23andMe-$666.70M-$15.45N/AN/AN/A-183.39%-170.07%-62.13%N/AOKYOOKYO Pharma-$4.71MN/AN/AN/AN/AN/AN/AN/A6/3/2026 (Estimated)PYRGFPyroGenesis Canada-$21.12M-$0.05N/AN/AN/A-115.14%N/A-60.81%N/ALatest ME, OKYO, IMA, and PYRGF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/10/2026Q4 2025IMAImageneBioN/A$0.34N/A$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMAImageneBioN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMAImageneBioN/A12.4912.49ME23andMeN/A1.050.91OKYOOKYO PharmaN/A0.58N/APYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMAImageneBio75.00%ME23andMe36.10%OKYOOKYO Pharma2.97%PYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipIMAImageneBio5.94%ME23andMe26.32%OKYOOKYO Pharma40.46%PYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMAImageneBio7010.65 million10.02 millionNot OptionableME23andMe77026.83 million19.77 millionNot OptionableOKYOOKYO Pharma740.56 million24.15 millionNot OptionablePYRGFPyroGenesis Canada90206.61 million96.34 millionNo DataME, OKYO, IMA, and PYRGF HeadlinesRecent News About These CompaniesPyroGenesis Schedules 2026 First Quarter Financial Results and Business Update Conference CallMay 1, 2026 | globenewswire.comPyroGenesis Provides Corporate Update on NexGen™ Titanium Metal Powder StrategyApril 29, 2026 | globenewswire.comPyroGenesis Announces Appointment of Jean Mayer as Vice-President, Legal Affairs and Corporate SecretaryApril 28, 2026 | globenewswire.comPyroGenesis Produces Battery-Grade Graphite from Carbon Black Using Proprietary Plasma SystemApril 23, 2026 | globenewswire.comPyroGenesis Canada (NASDAQ:PYRGF) Shares Up 5.3% - Here's WhyApril 21, 2026 | marketbeat.comPyroGenesis Announces Fourth Quarter and Full Year 2025 ResultsMarch 30, 2026 | globenewswire.comPyroGenesis Announces Closing of Non-Brokered Private PlacementMarch 26, 2026 | globenewswire.comPyroGenesis Schedules 2025 Fiscal Year Financial Results and Business Update Conference CallMarch 23, 2026 | globenewswire.comPyroGenesis Announces Oversubscription of Non-Brokered Private PlacementMarch 11, 2026 | globenewswire.comPyroGenesis Announces $1 Million Non-Brokered Private PlacementMarch 9, 2026 | globenewswire.comPyroGenesis Confirms Successful Primary Test Campaign with Leading Battery RecyclerMarch 6, 2026 | theglobeandmail.comPyroGenesis Completes Plasma Torch System Build for Constellium, Commences Delivery and Installation PhaseMarch 6, 2026 | globenewswire.comPyroGenesis Confirms Third-Party Verification of Its Fumed Silica: Successfully Meets Major Requirement for Proposed Joint VentureFebruary 19, 2026 | markets.businessinsider.comPyroGenesis Confirms Third-Party Verification of Its Fumed Silica: Successfully Meets Major ...February 19, 2026 | caledonianrecord.comCPyroGenesis Confirms Additional Independent Verification of Its Fumed Silica Meeting Commercial Grade “150”February 3, 2026 | globenewswire.comPyroGenesis Signs Agreement with U.S. Defense Contractor to Jointly Pursue Chemical Weapon Destruction Contracts in SyriaJanuary 6, 2026 | globenewswire.comPyroGenesis Provides 90-Day Cancellation Notice to EarthGridDecember 23, 2025 | globenewswire.comPyroGenesis Delivers 3.5 Tonnes of Titanium Powder Under New Powder Supply Agreement with U.S. Minerals and Metal Technology CompanyDecember 15, 2025 | globenewswire.comPyroGenesis Signs Plasma-Based Contract With Leading Battery RecyclerDecember 11, 2025 | globenewswire.comPyroGenesis Announces "Fine Cut” Titanium Powder Contract with U.S. Additive Manufacturing CompanyDecember 10, 2025 | manilatimes.netMPyroGenesis Announces “Fine Cut” Titanium Powder Contract with U.S. Additive Manufacturing CompanyDecember 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026NVIDIA's Quantum Computing Play Just Sent IonQ and Rigetti Flying By Jeffrey Neal Johnson | April 15, 2026ME, OKYO, IMA, and PYRGF Company DescriptionsImageneBio NASDAQ:IMA$5.83 +0.11 (+1.92%) Closing price 04:00 PM EasternExtended Trading$5.77 -0.06 (-1.03%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.23andMe NASDAQ:ME23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.OKYO Pharma NASDAQ:OKYO$1.60 -0.08 (-4.76%) Closing price 04:00 PM EasternExtended Trading$1.62 +0.02 (+1.56%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.PyroGenesis Canada NASDAQ:PYRGF$0.30 +0.01 (+1.80%) As of 02:16 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
